149281-55-0

Downstream Products

• 610797-63-2 4-oxo-4-(4-chlorophenyl)-2-[N-(4-ethoxycarbonylphenyl)]aminobut-2-enoic-acid 
• 1283714-85-1 (2Z)-4-(4-chlorophenyl)-2-[2-(9H-fluoren-9-ylidene)hydrazino]-4-oxobut-2-enoic acid 
• 1283714-87-3 4-(4-chlorophenyl)-2-[2-(9H-fluoren-9-ylidene)hydrazino]-4-oxobut-2-enoic acid 
• 1283714-71-5 4-(4-chlorophenyl)-2-{2-[(4-methoxyphenyl)-(phenyl)methylidene]hydrazino}-4-oxobut-2-enoic acid 
• 1283714-70-4 (2Z)-4-(4-chlorophenyl)-2-{(E)-2-[(4-methoxyphenyl)-(phenyl)methylidene]hydrazino}-4-oxobut-2-enoic acid 

Relevant academic research and scientific papers

4-phenyl-4-oxo-2-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity

PCT No. PCT/EP96/04517 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/17316 PCT Pub. Date May 15, 19974-Phenyl-4-oxo-butenoic acid derivatives for use in the treatment of the human or animal body by therapy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enzyme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butenoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.